# Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

> **NCT00268723** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Exercise-induced Bronchospasm

## Interventions

- **DRUG:** Levalbuterol tartrate HFA MDI
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00268723
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2012-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00268723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00268723, "Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00268723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*